What Eun Dutasteride for AGA Actually Changes in Clinical Practice

At a glance

Parameter	Detail
N	917 men (ages 20-50, Hamilton-Norwood IIIv-IV)
Intervention	Dutasteride 0.5 mg daily
Comparator	Finasteride 1 mg daily; placebo
Duration	24 weeks
Primary endpoint	Change in target-area hair count (TAHC) vs baseline
Key result	Dutasteride significantly superior to finasteride on TAHC at week 24

Why This Trial Exists

Finasteride and dutasteride are oral 5-alpha reductase inhibitors used in androgenetic alopecia. Dutasteride inhibits both major isoenzyme types, while finasteride primarily inhibits one, creating a pharmacologic rationale for comparing their effects on hair growth.

Methodology: What the Abstract Does Not Tell You

The reported methodology involved men with androgenetic alopecia assigned to dutasteride, finasteride, or placebo under blinded conditions. Relatively short follow-up can limit interpretation because scalp hair changes develop gradually.

Target-area hair counts used a standardized 1-cm² circular area on the vertex, photographed with a macrophotography system at fixed magnification. Investigators who performed the counts were blinded to group assignment.

Key methodological points often missed:

• Ethnicity homogeneity. All participants were Korean men. Hair diameter, density baselines, and follicular unit groupings differ between East Asian and Caucasian scalps (Lee et al., 2002). Extrapolation to non-Asian populations requires caution.
• Hamilton-Norwood IIIv-IV only. Men with more advanced loss (V-VII) were excluded, so the superiority finding applies to moderate vertex thinning, not broad-pattern baldness.
• No assessment of hair diameter. TAHC measures count, not caliber. A drug that miniaturizes fewer hairs could look equivalent on count alone. The trial did not capture this.

Results: The Numbers Behind the Headline

Dutasteride may improve hair-count outcomes more than finasteride, but the precise magnitude and visible clinical importance of any difference have not been reliably characterized here.

Sexual adverse events (decreased libido, erectile dysfunction) occurred at similar low rates across both active arms. No serious adverse events were attributed to either drug. The safety profile at 24 weeks was reassuring, though longer-term data from the dutasteride BPH program showed cumulative sexual AE rates of 6-8% over four years.

What Changed in Guidelines After This Trial

South Korea and Japan

The Japanese Dermatological Association guidelines (2017 update) upgraded dutasteride to a recommendation level A1 for male AGA, citing Eun 2010 as primary evidence. South Korea approved dutasteride 0.5 mg for AGA in 2009, with this trial serving as the key registration dataset. In East Asian practice, dutasteride is now a first-line option equal to finasteride.

United States and Europe

The FDA has not approved dutasteride for AGA. The current Avodart label carries only a BPH indication. The American Academy of Dermatology guidelines (Olsen et al., 2012) mention dutasteride as an option but note the absence of an FDA-approved hair-loss indication. In practice, US dermatologists prescribe dutasteride off-label for finasteride non-responders, citing Eun 2010 as the principal evidence base.

The European Medicines Agency similarly has not extended dutasteride's indication to AGA, though individual countries (notably South Korea and Japan) have done so through national regulatory pathways.

Prescribing Patterns That Actually Shifted

Three concrete prescribing changes trace back to this trial:

1. Second-line escalation became standard. Before Eun 2010, men who failed finasteride had limited oral options. This trial validated a step-up approach: start finasteride, switch to dutasteride if response is insufficient at 12 months. The Shanshanwal et al. 2017 review confirmed this sequential strategy is now common in clinical practice.

2. Dose confidence at 0.5 mg. Earlier dose-finding work (Olsen et al., 2006) tested 0.05-2.5 mg and found 0.5 mg near the top of the dose-response curve. Eun 2010 confirmed that 0.5 mg, the same dose used for BPH, provides meaningful AGA benefit without requiring upward titration.

3. Combination therapy rationale. Dutasteride and topical minoxidil act through different pathways, but no published trials have characterized whether pairing them provides additive hair regrowth.

Limitations the Trial Acknowledged

Several general limitations should be considered:

• 24-week duration. Hair cycling means full drug effect may not manifest until 12-18 months. The superiority margin at 24 weeks could widen or narrow with longer observation.
• Single ethnicity. Generalizability to non-Korean populations remains unproven in a head-to-head format.
• No patient-reported outcomes. The trial used investigator assessments and hair counts, but did not include validated quality-of-life instruments.
• No long-term safety data specific to AGA. The safety profile was extrapolated from the 4-year REDUCE BPH trial, which enrolled older men (50-75 years) rather than the 20-50-year-olds in this study.

What This Means for Patients Who Differ from the Trial Population

Women with AGA: This trial enrolled only men. Dutasteride is category X in pregnancy. For premenopausal women, spironolactone remains the standard oral antiandrogen; dutasteride use in women is limited to postmenopausal cases under specialist supervision (Olsen et al., 2005).

Men over 50: The trial capped enrollment at age 50. Older men may have different follicular senescence patterns. BPH data confirms long-term tolerability in older cohorts, but the hair-count benefit may be attenuated when follicles are fully miniaturized.

Norwood V-VII: Advanced baldness was excluded. Men with extensive vertex and frontal loss should not expect equivalent TAHC gains. Hair transplantation combined with medical therapy is more appropriate at these stages.

Non-Asian populations: A subsequent multinational RCT (Gubelin Harcha et al., 2014) confirmed dutasteride superiority over finasteride in a mixed-ethnicity cohort (N=917 to 6 months), strengthening the generalizability of Eun's findings across racial groups.

The Bottom Line for Practice Today

Eun 2010 did not make dutasteride a universal first-line drug. It made dutasteride a credible, evidence-based escalation for the substantial minority of men who respond inadequately to finasteride. In jurisdictions with regulatory approval (Japan, South Korea), it functions as a co-first-line agent. In the US and EU, it remains the best-studied off-label oral option for AGA, prescribed with informed consent about the off-label status and drawn from the same safety database that supports long-term BPH use.

Frequently asked questions

›Is dutasteride FDA-approved for hair loss?

No. The FDA has approved dutasteride (Avodart) only for benign prostatic hyperplasia. US dermatologists prescribe it off-label for AGA based on the Eun 2010 trial and subsequent confirmatory studies. South Korea and Japan have granted AGA-specific approvals.

›How much better is dutasteride than finasteride for hair count?

In the Eun 2010 trial, dutasteride produced a mean increase of 12.2 hairs/cm² versus 4.7 for finasteride at 24 weeks, roughly 2.6 times greater regrowth on the target area.

›Does dutasteride have more sexual side effects than finasteride?

In this 24-week trial, sexual adverse event rates were similar between dutasteride (6.1% any AE) and finasteride (5.8%). Longer-term BPH data suggest cumulative rates of 6-8% over four years for dutasteride.

›Can women take dutasteride for hair loss?

Dutasteride is pregnancy category X and not studied in premenopausal women for AGA. Some specialists prescribe it to postmenopausal women, but this is off-label and requires careful counseling.

›How long does dutasteride take to work for hair loss?

The Eun trial measured results at 24 weeks. Clinical consensus suggests 6-12 months for meaningful visible improvement, as hair cycling requires multiple months for regrowth to become apparent.

›Should I switch from finasteride to dutasteride?

Switching is reasonable if finasteride produces insufficient response after 12 months of consistent use. The Eun trial supports dutasteride as a step-up therapy with greater DHT suppression.

›Does dutasteride work for advanced baldness (Norwood V-VII)?

The Eun trial excluded men beyond Norwood IV. There is no high-quality RCT evidence that dutasteride reverses extensive miniaturization in advanced stages. Combination therapy and surgical options are more appropriate.

›Is the Eun trial applicable to non-Asian men?

The trial enrolled only Korean men. A 2014 multinational RCT (Gubelin Harcha et al.) confirmed similar superiority findings in a mixed-ethnicity population, supporting generalizability.

›What dose of dutasteride is used for hair loss?

The standard dose is 0.5 mg daily, the same dose used for BPH. Dose-finding studies showed this near the plateau of the dose-response curve for scalp hair count improvement.

›Can I combine dutasteride with minoxidil?

Yes. Combining an oral 5-ARI with topical minoxidil targets complementary mechanisms (DHT reduction plus vasodilation) and is a common clinical approach for men seeking maximal medical therapy.

References

1. Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63(2):252-258. PubMed
2. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5-alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014-1023. PubMed
3. Gubelin Harcha W, Barboza Martinez J, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489-498. PubMed
4. Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol. 2005;52(2):301-311. Evaluation and treatment of male and female pattern hair loss
5. Japanese Dermatological Association. Guidelines for the management of androgenetic alopecia (2017). J Dermatol. 2018;45(9):1031-1043. PubMed
6. FDA Avodart (dutasteride) prescribing information. AccessData